Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma

Urology

Volumn 63, Issue 6, 2004, Pages 1055-1060

  Chautard, Denis ^a   Dalifard, Isabelle ^b   Chassevent, Agnes ^b   Guyetant, Serge ^b   Daver, Alain ^b   Vielle, Bruno ^b   Soret, Jean Yves ^b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN INHIBITOR TYPE 1; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; DNA CONTENT; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; CARCINOMA, RENAL CELL; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 2942548223     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.01.013     Document Type: Article

References (25)

1. Baisch H., Otto U., Konig K., et al. DNA content of human kidney carcinoma cells in relation to histological grading. Br J Cancer. 45:1982;878-886
2. Grignon D.J., Ayala A.G., el-Naggar A., et al. Renal cell carcinoma a clinicopathologic and DNA flow cytometric analysis of 103 cases. Cancer. 64:1989;2133-2140
3. Currin S.M., Lee S.E., Walther P.J. Flow cytometric assessment of deoxyribonucleic acid content in renal adenocarcinoma does ploidy status enhance prognostic stratification over stage alone? J Urol. 143:1990;458-463
4. Ljungberg B., Larsson P., Stenling R., et al. Flow cytometric deoxyribonucleic acid analysis in stage I renal cell carcinoma. J Urol. 146:1991;697-699
5. Ljungberg B., Mehle C., Stenling R., et al. Heterogeneity in renal cell carcinoma and its impact on prognosis - a flow cytometric study. Br J Cancer. 74:1996;123-127
6. Papadopoulos I., Rudolph P., Weichert-Jacobsen K. Value of p53 expression, cellular proliferation, and DNA content as prognostic indicators in renal cell carcinoma. Eur Urol. 32:1997;110-117
7. Ruiz-Cerda J.L., Hernandez M., Sempere A., et al. Intratumoral heterogeneity of DNA content in renal cell carcinoma and its prognostic significance. Cancer. 86:1999;664-671
8. Di Silverio F., Casale P., Colella D., et al. Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma. Cancer. 88:2000;835-843
9. Abou-Rebyeh H., Borgmann V., Nagel R., et al. DNA ploidy is a valuable predictor for prognosis of patients with resected renal cell carcinoma. Cancer. 92:2001;2280-2285
10. Andreasen PA, Kjoller L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72:1-22, 1997
11. Los M., Zeamari S., Foekens J.A., et al. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. Cancer Res. 59:1999;4440-4445
12. Xu Y., Hagege J., Doublet J.D., et al. Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma. Hum Pathol. 28:1997;206-213
13. Pyke C., Kristensen P., Ralfkiaer E., et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol. 138:1991;1059-1067
14. Foekens J.A., Schmitt M., van Putten W.L., et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol. 12:1994;1648-1658
15. Storkel S., Eble J.N., Adlakha K., et al. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Classification of renal cell carcinoma Workgroup No. 1. Cancer. 80:1997;987-989
16. Sobin L.H., Fleming I.D. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. TNM Classification of Malignant Tumors, 5th ed (1997). Cancer. 80:1997;1803-1804
17. Fuhrman S.A., Lasky L.C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:1982;655-663
18. Vindelov L.L., Christensen I.J., Nissen N.I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 3:1983;323-327
19. Ronne E., Hoyer-Hansen G., Brunner N., et al. Urokinase receptor in breast cancer tissue extracts enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat. 33:1995;199-207
20. Hofmann R., Lehmer A., Hartung R., et al. Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J Urol. 155:1996;858-862
21. Swiercz R., Wolfe J.D., Zaher A., et al. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. Clin Cancer Res. 4:1998;869-877
22. Pepe S., Ruggiero A., D'Acquisto M., et al. Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas. Cancer. 89:2000;1065-1075
23. Bringuier P.P., Bouvier R., Berger N., et al. DNA ploidy status and DNA content instability within single tumors in renal cell carcinoma. Cytometry. 14:1993;559-564
24. Katusin D., Uzarevic B., Petrovecki M., et al. Clinical, histopathological and flow-cytometric properties of incidental renal cell carcinomas. Urol Res. 28:2000;52-56
25. Elfving P., Mandahl N., Lundgren R., et al. Prognostic implications of cytogenetic findings in kidney cancer. Br J Urol. 80:1997;698-706